Amifostine (WR2721) confers DNA protection to in vivo cisplatin-treated murine peripheral blood leukocytes.
Amifostine [S-2-3-aminopropyl amino ethyl phosphorotioic acid], a modulator agent for antineoplastic drugs involved in free radicals generation has given controversial results in cisplatin treated leukocytes in vitro. We have evaluated the amifostine protection over leukocytes in vivo, using comet assay. Groups of five OF1 male mice were given one of three doses of amifostine (56, 105 and 200 mg/Kg) after a cisplatin single injection (10 mg/Kg). Serum malonyldialdehyde levels, catalase and superoxide dismutase activity were also evaluated. Amifostine showed significant DNA protection (p< 0.01) at the two lower doses evaluated. Malonyldialdehyde decreased in all amifostine treatments with respect to cisplatin while antioxidant enzyme activities remained unchanged. However, DNA migration increased with the highest amifostine dose; in fact highest dose of amifostine did no protect damage caused by cisplatin this result have implications on amifostine treatment schedules in clinical practice.
Prieto González
E A
EA
Centro de Altos Estudios en Ciencias de la Salud, Universidad Abierta Interamericana, Ave. Montes de Oca. No. 745, Buenos Aires Capital, Federal Argentina. EPrietto@vaneduc.edu.ar
Fuchs
A G
AG
Sánchez
González S
GS